Mayne Pharma Group Limited
Mayne Pharma Group Limited (MAYNF) Financial Performance & Income Statement Overview
Explore the financials of Mayne Pharma Group Limited (MAYNF), including yearly and quarterly data on income, cash flow, and balance sheets.
Mayne Pharma Group Limited (MAYNF) Income Statement & Financial Overview
Explore comprehensive income reports for Mayne Pharma Group Limited MAYNF, broken down by year and quarter.
| Metric | Q4 2024 | Q2 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|
| Revenue | $200.47M | $187.93M | $82.42M | $41.21M |
| Cost of Revenue | $87.48M | $113.61M | $38.72M | $3.41M |
| Gross Profit | $112.99M | $74.32M | $43.70M | $37.80M |
| Gross Profit Ratio | $0.56 | $0.40 | $0.53 | $0.92 |
| R&D Expenses | $10.65M | $10.24M | $7.35M | $4.15M |
| SG&A Expenses | $109.60M | $102.91M | $100.53M | $65.98M |
| Operating Expenses | $120.25M | $113.16M | $107.89M | $89.60M |
| Total Costs & Expenses | $207.73M | $226.76M | $146.60M | $93.02M |
| Interest Income | $3.002M | $4.06M | $4.04M | $225000.00 |
| Interest Expense | $2.40M | $2.30M | $3.59M | $0.00 |
| Depreciation & Amortization | $29.97M | $35.88M | $36.27M | $18.59M |
| EBITDA | $23.37M | -$2.96M | -$27.91M | -$13.27M |
| EBITDA Ratio | $0.12 | -$0.02 | -$0.34 | -$0.32 |
| Operating Income | -$7.26M | -$38.84M | -$64.18M | -$31.86M |
| Operating Income Ratio | -$0.04 | -$0.21 | -$0.78 | -$0.77 |
| Other Income/Expenses (Net) | -$107.96M | -$36.03M | -$38.98M | -$19.72M |
| Income Before Tax | -$115.22M | -$74.86M | -$103.16M | -$51.58M |
| Income Before Tax Ratio | -$0.57 | -$0.40 | -$1.25 | -$1.25 |
| Income Tax Expense | -$17.15M | -$4.32M | $85.11M | $42.55M |
| Net Income | -$103.68M | -$70.55M | -$171.84M | -$94.14M |
| Net Income Ratio | -$0.52 | -$0.38 | -$2.08 | -$2.28 |
| EPS | -$1.28 | -$0.87 | -$2.06 | -$1.15 |
| Diluted EPS | -$1.31 | -$0.87 | -$2.06 | -$1.15 |
| Weighted Avg Shares Outstanding | $81.25M | $81.25M | $83.42M | $81.96M |
| Weighted Avg Shares Outstanding (Diluted) | $78.88M | $81.25M | $83.42M | $81.96M |
Over the last four quarters, Mayne Pharma Group Limited's revenue moved from $41.21M in Q3 2023 to $200.47M in Q4 2024. Operating income in Q4 2024 was -$7.26M, with a strong operating margin of -4%. Despite fluctuations in R&D and SG&A expenses, EBITDA for Mayne Pharma Group Limited remained robust at $23.37M, reflecting operational efficiency. Net income dropped to -$103.68M, with an EPS of -$1.28. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan